Evidence map›Paper›PMID 40272937›Full record

ArticleClinical and translational gastroenterology2025

Statin Use Is Associated With Protection Against Acute Cholangitis in Patients With Primary Sclerosing Cholangitis: A Multicenter Retrospective Cohort Study.

Chiraag Kulkarni, George Cholankeril, Touran Fardeen, Joseph Rathkey, Samir Khan, Soumya Murag, Robert Lerrigo, Ahmad Kamal, Ajitha Mannalithara, Prasun Jalal and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Response to Cardinale et al.Clinical and translational gastroenterology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chiraag KulkarniDivision of Gastroenterology & Hepatology, Department of Medicine, Stanford University, Palo Alto, California, USA.ORCID 0000-0002-8354-3566
George CholankerilSection of Gastroenterology & Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Touran FardeenDivision of Gastroenterology & Hepatology, Department of Medicine, Stanford University, Palo Alto, California, USA.
Joseph RathkeyDivision of Gastroenterology & Hepatology, Department of Medicine, Stanford University, Palo Alto, California, USA.
Samir KhanSection of Gastroenterology & Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Soumya MuragSanta Clara Valley Medical Center, Santa Clara, California, USA.
Robert LerrigoSanta Clara Valley Medical Center, Santa Clara, California, USA.
Ahmad KamalSanta Clara Valley Medical Center, Santa Clara, California, USA.
Ajitha MannalitharaDivision of Gastroenterology & Hepatology, Department of Medicine, Stanford University, Palo Alto, California, USA.
Prasun JalalSection of Gastroenterology & Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Aijaz AhmedDivision of Gastroenterology & Hepatology, Department of Medicine, Stanford University, Palo Alto, California, USA.
John VierlingSection of Gastroenterology & Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Aparna GoelDivision of Gastroenterology & Hepatology, Department of Medicine, Stanford University, Palo Alto, California, USA.
Sidhartha R SinhaDivision of Gastroenterology & Hepatology, Department of Medicine, Stanford University, Palo Alto, California, USA.ORCID 0000-0001-5104-6410

Funding

American College of Gastroenterology, Paul G. Allen Frontiers Group, Leona M. and Harry B. Helmsley Charitable Trust 2007-04026
6 · The paper itself

Abstract

introductionPatients with primary sclerosing cholangitis (PSC) are at increased risk of acute cholangitis. The epidemiological risks of cholangitis are poorly studied despite the high morbidity associated with this infection. The aim of this study was to understand the impact of statins on acute cholangitis in PSC.

methodsThis multicenter, retrospective cohort study assessed data from 294 patients with PSC at Stanford Medical Center, Baylor Medical Center, and Valley Medical Center. Clinical factors associated with the development of cholangitis were identified using multivariable Cox regression.

resultsThe patients were predominantly male (68.7%) with a median age at enrollment of 48 years (interquartile range [IQR]: 31.0-60.8). Fifty patients (17.0%) were prescribed statins. The median follow-up time was 6 years (IQR: 2.0-12.0), in which 29.6% (n = 87) developed cholangitis. In multivariable analysis, statins were associated with an 81% reduction in cholangitis (HR 0.19, 95% confidence interval 0.03-0.64). Statins were associated with a lower adjusted incidence of cholangitis at 36 months compared with patients not on statin therapy (incidence of 2.8% vs 12.2%, P < 0.001). Statins were also associated with increased time-to-stricture ( P = 0.004), an outcome known to be associated with PSC complications. DISCUSSION: Statin therapy is associated with reduced risk of cholangitis in PSC, possibly by delaying the time to develop dominant or high-grade strictures. In patients with PSC, use of statin therapy may be a beneficial modality to prevent the development of cholangitis and warrants further investigation.

Indexed as

CholangitisCholangitis, SclerosingHydroxymethylglutaryl-CoA Reductase InhibitorsAcute DiseaseAdultFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsHydroxymethylglutaryl-CoA Reductase Inhibitorsacute cholangitisdominant strictureprimary sclerosing cholangitisstatins

Identifiers

PMID40272937
PMCPMC12020706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.